Anna Mudge

Anna’s work involves IP strategy, drafting, prosecution, and oppositions in the life sciences sector.  She has particular expertise in drafting and prosecuting robust patent portfolios and has a successful track record in offensive oppositions at the EPO.  She also has extensive experience leading large, high-value freedom-to-operate projects.

Anna leads the firm’s Advanced Therapeutics team which focuses on cell and gene therapies. 

Areas of Expertise

• Cell therapies
• Gene therapies
• Nucleic acid and antisense technologies
• Immunotherapies
• Antibody technologies

Clients

Anna works with a wide range of organisations, from biotech start-ups and universities to multinational pharmaceutical companies. She always endeavours to become a trusted advisor to her clients, whatever their commercial and IP requirements.  Many of her clients are based in the UK, Singapore and the USA, and she is a regular visitor to the East Coast of the US. 

Background

Anna has a first class BSc in Molecular Biology and Biochemistry and a PhD, both from Durham University. Her doctorate specialised in the molecular mechanisms of plant root growth. She joined Mewburn Ellis LLP in 2015, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2019. Anna joined the partnership in 2024. 

Opposition Highlights

Anna has worked on numerous successful offensive EPO oppositions of high commercial importance.  Recent highlights before the EPO’s Opposition Divisions include:

• Revocation of EP3636778 relating to antisense nucleic acid molecules for treating facioscapulohumeral muscular dystrophy;
• Revocation of EP2806900 relating to antisense oligonucleotides for treating Duchenne and Becker muscular dystrophy;
• Revocation of EP2654789 relating to anti-CD39 antibodies.

Recommendations

Anna is named as a ‘Rising Star’ in Managing Intellectual Property’s IP Stars 2022, 2023 and 2024.